
There Are Two New Drugs to Treat Gonorrhea
The FDA approved two new drugs to treat gonorrhea The new drugs—gepotidacin and zoliflodacin—are both new kinds of antibiotics and represent the first completely new treatment options in over thirty years.
A new fully at-home test for chlamydia, gonorrhea, and trichomoniasis is now available for online purchase, and users in certain major cities can even order it through DoorDash or Gopuff.
The Visby Medical Women’s Sexual Health Test, which won FDA approval in March, comes with its own testing device that plugs into an electrical outlet. Users also need to download the companion app which will provide instructions for collecting a vaginal sample, using the device, and uploading a picture of the results. The device processes a PCR test similar to those done in laboratories and offers results in 30 minutes.
The sexual health test—which is only for women—can be purchased on Visby’s website or through online health testing site Everlywell for $149.99. Most people will receive it in the mail, but users in 10 major cities, including San Francisco, Las Vegas, New York, and Atlanta, may be able to get same-day delivery through DoorDash or Gopuff. (Visby’s website helps find the fastest option for users.) The test looks for chlamydia, gonorrhea, and trichomoniasis, but can only be used once.
Anyone who tests positive will be offered a same-day telehealth appointment via the Optum Now network. The telehealth appointment is included in the price of the test. For people who prefer to see their own provider, the app will prepare a PDF of the results that can be sent to a provider via a patient portal or printed out and brought to an appointment.
At-home STI testing has become more popular in recent years because it is private and convenient. There are many kits on the market today that let users collect their own sample, but most of them need to be mailed to a lab for results. Until now, the only tests that offered immediate results at home were an oral HIV test and a test for syphilis that uses a drop of blood from a finger prick.
Expanding testing options is important. There were more than 1.5 million cases of chlamydia and over 500,000 cases of gonorrhea reported 2024. In addition, the CDC estimates that at any given time, 2.6 million people trichomoniasis (often called trich), though exact numbers are not known because cases do not have to be reported.
The CDC estimates that there are many more infections each year that go undiagnosed because these STIs often have no symptoms. If diagnosed early, all of these infections can be cured with antibiotics. When left untreated, however, they can cause serious health issues including infertility. That’s why regular testing is so important.
At-home STI testing may help more people get tested because it can be easier to coordinate than in-person testing. It can also be good for people who don’t feel ready to talk about their sexual health with a health care provider. A recent study found that 70% of young people say they would prefer testing for STIs at home over going to a doctor’s office or clinic. Respondents cited convenience, privacy, and comfort as reasons why they preferred STI self-collection kits.
There are now many ways to test at home. Visby’s new test is good at-home option because results are given right away, and telehealth follow-up is included. However, the test is more expensive than other options. There are many other online companies—such as Nurx, TBD Health, Lemonaid, Let’s Get Checked, and myLAB—that sell test kits for STIs including chlamydia, gonnorhea, and trich. Similar tests are also available in pharmacies. Results for these tests take longer because these tests have to be mailed to a lab, but they are less expensive. Some health departments also offer at-home test kits that can be picked up or set by mail. There may also be free at-home testing kits available in some areas.
All of these tests provide accurate results so everyone can pick what option works best for them. The most important thing is to get tested and get any follow up care needed as soon as possible.

The FDA approved two new drugs to treat gonorrhea The new drugs—gepotidacin and zoliflodacin—are both new kinds of antibiotics and represent the first completely new treatment options in over thirty years.

The American Cancer Society (ACS) released new recommendations for cervical cancer screening that focus on HPV testing and approve the use of self-collected samples. The recommendations also clarify the age at which screening should start and stop.

Public health officials in England announced that they have identified a new combined type of mpox. Tests show the virus was a unique mix of the two known types of mpox and experts are concerned about what this means for future spread of the virus.

A committee that advises the Centers for Disease Control and Prevention (CDC) made an alarming change to the recommendations for the hepatitis B vaccine that will leave some infants unprotected.

The Centers for Disease Control and Prevention (CDC) recently made striking changes to its online information about the connection between vaccines and autism that put the agency on the wrong side of science.

A new report from the World Health Organization (WHO) warns of rising levels of drug-resistant gonorrhea. The data comes from reported cases of gonorrhea in 12 countries across five WHO regions.

We’ve known for years that the HPV vaccine works. Now new research shows that widespread vaccination even protects those who haven’t gotten the shot. This study proves that it is possible to reach herd immunity for HPV.

A more serious type of mpox may be spreading California. Three people in the state were hospitalized with the virus.
ASHA believes that all people have the right to the information and services that will help them to have optimum sexual health. We envision a time when stigma is no longer associated with sexual health and our nation is united in its belief that sexuality is a normal, healthy, and positive aspect of human life.
ABOUT
GET INVOLVED
ASHA WEBSITES
GET HELP
© 2025 American Sexual Health Association